About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

RO7204239

Company: Hoffmann-La Roche
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 30, 2026

Trial details

Completed NCT NCT04708847

A Clinical Pharmacology Study to Evaluate the Effect of GYM329 on Disuse Muscle Atrophy in Healthy Volunteer

Not yet reported Chugai Pharmaceutical 30 participants Est. completion 2023-02-01 1 site Stand-alone

Other conditions: Healthy Volunteers
View official trial listing →
Active, not recruiting NCT NCT05115110

A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy

Not yet reported, Not yet reported Hoffmann-La Roche 97 participants Est. completion 2026-10-28 30 sites Stand-alone

Other conditions: Spinal Muscular Atrophy (SMA)
View official trial listing →
Active, not recruiting NCT NCT05548556

A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

Not yet reported Hoffmann-La Roche 51 participants Est. completion 2026-10-09 9 sites Stand-alone

Other conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)
View official trial listing →
Active, not recruiting NCT NCT06965413

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

Not yet reported Hoffmann-La Roche 285 participants Est. completion 2027-03-31 35 sites Added to GLP-1

Other conditions: Obesity, Overweight, Overweight With One Weight Related Comorbidity
View official trial listing →
Active, not recruiting NCT NCT07137585

A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity

Not yet reported Hoffmann-La Roche 30 participants Est. completion 2027-02-28 1 site Stand-alone

Type 2 diabetes Other conditions: Obesity, Overweight
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT07137585

Also known as: RO7204239, GYM329

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.